Gland Pharma Q3 Results Shine: Revenue Up 22%, Cenexi Turns Profitable

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorVihaan Mehta|Published at:
Gland Pharma Q3 Results Shine: Revenue Up 22%, Cenexi Turns Profitable
Overview

Gland Pharma posted a strong Q3 FY26, with consolidated revenue climbing 22% year-on-year to INR 16,954 million and adjusted EBITDA surging 25% to INR 4,490 million, achieving a healthy 26% margin. A key highlight was the turnaround of its European subsidiary, Cenexi, which turned profitable with positive EBITDA. The company plans INR 2,000 crore capex over five years, targeting 15% CAGR growth in high-end CDMO and specialty injectables.

📉 The Financial Deep Dive

The Numbers: Gland Pharma delivered a robust performance in Q3 FY26. Consolidated revenue grew a significant 22% year-on-year to INR 16,954 million. Adjusted EBITDA saw an even stronger increase of 25% year-on-year, reaching INR 4,490 million. This translated into a healthy EBITDA margin of 26%, up from the previous year.

For the first nine months of FY26, revenue stood at INR 46,879 million, marking a 12% year-on-year growth. The adjusted EBITDA margin for 9M FY26 improved to 25%, indicating better operational efficiency and profitability over the period.

The Quality: A critical development is the successful turnaround of its European subsidiary, Cenexi. After struggling, Cenexi reported a positive EBITDA of EUR 1.4 million (INR 148 million) in Q3 FY26, meeting management guidance and significantly contributing to the group's profitability. This turnaround is a key indicator of Gland Pharma's ability to manage and revive its international operations.

Operating cash flow for 9M FY26 was robust at INR 6,269 million, demonstrating the company's ability to generate cash from its core business. Capex for the same period was INR 3,566 million.

The Grill: Management expressed strong confidence in sustaining this growth momentum. The outlook is supported by planned product launches, ramp-up of CDMO contracts, and new capacities coming online. A significant strategic initiative involves an approximate INR 2,000 crore investment in capital expenditure over the next five years. This capex is earmarked for expanding capacities in Blow-Fill-Seal (BFS) and ophthalmic lines, and for CDMO contracts, aiming to double the company's gross block. The company has also increased R&D investment to 5.4% of revenue in Q3 FY26, focusing on complex injectables and advanced delivery systems, filing nine ANDAs and launching ten new products in the U.S. The company reiterates its strategic goal to evolve into a high-end, innovation-led CDMO and specialty injectables company, targeting an organic growth of 15% CAGR over five years.

🚩 Risks & Outlook

While the outlook is positive, investors should monitor the execution of the ambitious INR 2,000 crore capex plan. Delays or cost overruns could impact profitability. The competitive landscape in CDMO and specialty injectables requires continuous innovation and efficient capacity utilization. The U.S. launch of Liraglutide, following European approvals, will be a key event to watch in the near term. The company's ability to scale up CDMO partnerships and leverage its expanded capacities will be crucial for achieving the stated 15% CAGR target.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.